These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36177835)

  • 1. Cost-Effectiveness of Intensive Versus Standard Blood Pressure Treatment in Older Patients With Hypertension in China.
    Fan J; Zheng W; Liu W; Xu J; Zhou L; Liu S; Bai J; Qi Y; Huang W; Liu K; Cai J
    Hypertension; 2022 Nov; 79(11):2631-2641. PubMed ID: 36177835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
    Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
    JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
    Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
    PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.
    Bress AP; Bellows BK; King JB; Hess R; Beddhu S; Zhang Z; Berlowitz DR; Conroy MB; Fine L; Oparil S; Morisky DE; Kazis LE; Ruiz-Negrón N; Powell J; Tamariz L; Whittle J; Wright JT; Supiano MA; Cheung AK; Weintraub WS; Moran AE;
    N Engl J Med; 2017 Aug; 377(8):745-755. PubMed ID: 28834469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.
    Zhang W; Zhang S; Deng Y; Wu S; Ren J; Sun G; Yang J; Jiang Y; Xu X; Wang TD; Chen Y; Li Y; Yao L; Li D; Wang L; Shen X; Yin X; Liu W; Zhou X; Zhu B; Guo Z; Liu H; Chen X; Feng Y; Tian G; Gao X; Kario K; Cai J;
    N Engl J Med; 2021 Sep; 385(14):1268-1279. PubMed ID: 34491661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
    Zhang L; Lin Z; Yin H; Liu J; Xuan J
    Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering: Results From the STEP Randomized Trial.
    Yang R; Huang R; Zhang L; Li D; Luo J; Cai J
    Hypertension; 2023 Dec; 80(12):2572-2580. PubMed ID: 37814892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of new blood pressure target for hypertensive patients in Taiwan according to the 2022 hypertension clinical practice guidelines of the Taiwan society of cardiology: a simulation modeling study.
    Liao CT; Toh HS; Yang CT; Hsu CY; Lee MC; Chang WT; Chen ZC; Chang HY; Strong C
    Hypertens Res; 2023 Jan; 46(1):187-199. PubMed ID: 36229527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
    Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
    Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Drug Treatment for Chinese Patients With Stage I Hypertension According to the 2017 Hypertension Clinical Practice Guidelines.
    Zhou YF; Liu N; Wang P; Jeong Yang J; Song XY; Pan XF; Zhang X; He M; Li H; Gao YT; Xiang YB; Wu T; Yu D; Pan A
    Hypertension; 2020 Sep; 76(3):750-758. PubMed ID: 32713271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Intensive Blood Pressure Management.
    Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
    JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study.
    Penaloza-Ramos MC; Jowett S; Barton P; Roalfe A; Fletcher K; Taylor CJ; Hobbs FR; McManus RJ; Mant J
    Eur J Prev Cardiol; 2016 Oct; 23(15):1590-8. PubMed ID: 27226338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of a Multicomponent Primary Care Intervention for Hypertension.
    Chay J; Jafar TH; Su RJ; Shirore RM; Tan NC; Finkelstein EA
    J Am Heart Assoc; 2024 Apr; 13(8):e033631. PubMed ID: 38606776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial.
    Upadhya B; Rocco M; Lewis CE; Oparil S; Lovato LC; Cushman WC; Bates JT; Bello NA; Aurigemma G; Fine LJ; Johnson KC; Rodriguez CJ; Raj DS; Rastogi A; Tamariz L; Wiggers A; Kitzman DW;
    Circ Heart Fail; 2017 Apr; 10(4):. PubMed ID: 28364091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of intensive blood pressure control in Korea.
    Lee YS; Lee HY; Kim TH
    Hypertens Res; 2022 Mar; 45(3):507-515. PubMed ID: 34934160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
    Williamson JD; Supiano MA; Applegate WB; Berlowitz DR; Campbell RC; Chertow GM; Fine LJ; Haley WE; Hawfield AT; Ix JH; Kitzman DW; Kostis JB; Krousel-Wood MA; Launer LJ; Oparil S; Rodriguez CJ; Roumie CL; Shorr RI; Sink KM; Wadley VG; Whelton PK; Whittle J; Woolard NF; Wright JT; Pajewski NM;
    JAMA; 2016 Jun; 315(24):2673-82. PubMed ID: 27195814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of drug treatment for young and middle-aged stage 1 hypertensive patients with high risk.
    Zhou YF; Deng H; Wang GD; Chen S; Xing A; Wang Y; Zhao H; Gao J; Wu S
    J Glob Health; 2023 Nov; 13():04147. PubMed ID: 37997845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Hypertension Duration on the Cardiovascular Benefit of Intensive Blood Pressure Control.
    Ling Q; Dong X; Bai J; Deng Y; Song Q; Cai J
    Hypertension; 2024 Sep; 81(9):1945-1955. PubMed ID: 39016010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.